This Blog Is Powered By Life Technology™. Visit Life Technology™ At www.lifetechnology.com Subscribe To This Blog Via Feedburner / Atom 1.0 / RSS 2.0.
News
Life Technology™ Medical News Subscribe Via Feedburner Subscribe Via Google Subscribe Via RSS
Life Technology™ Science News Subscribe Via Feedburner Subscribe Via Google Subscribe Via RSS
Life Technology™ Technology News Subscribe Via Feedburner Subscribe Via Google Subscribe Via RSS
ews&detail=-1&showtitle=false&type=js">
Saturday, September 28, 2019
Android 10 Go edition will bring speed, security gains
Google is bringing out its updated Android 10 version of Android Go. Google said, "we launched Android (Go edition) in 2018—a platform tailored for smartphones with 1.5GB of memory or less." Now Google has announced Android 10 (Go Edition), the version of Android built specifically for entry-level devices with 1.5GB RAM or less.
Three more elephants killed in Sri Lanka, bringing toll to seven
Wildlife officials found three more dead wild elephants in central Sri Lanka Saturday, raising the number believed to have been poisoned by angry villagers to seven.
Ovarian cancer: more women benefit from maintenance combined targeted therapy
New data presented at the ESMO Congress 2019 in Barcelona, Spain, show the benefit of a more intensive maintenance regimen for ovarian cancer with the PARP inhibitor olaparib added to bevacizumab, in an all-comers population, with and without a BRCA mutation. According to late breaking results of the PAOLA-1/ENGOT-ov25 trial, this approach extends progression free survival in patients with advanced ovarian cancer.
Two immunotherapy drug combination offers chemotherapy-free option for advanced NSCLC
New data have shown that first-line treatment with a combination of two immunotherapy drugs improves overall survival in a subset of patients with advanced non-small cell lung cancer (NSCLC) compared to chemotherapy.
Front-line osimertinib improves overall survival in EGFR-mutation positive NSCLC
First-line osimertinib significantly lengthens overall survival compared to older generation EGFR-TKIs in patients with Ex19del/L858R EGFR mutated advanced non-small cell lung cancer (NSCLC), according to late breaking results of the FLAURA trial presented at the ESMO Congress 2019 in Barcelona, Spain.
New treatment improves survival in women newly diagnosed with advanced ovarian cancer
An international study demonstrates that administering niraparib after conventional chemotherapy treatment in patients newly diagnosed with advanced ovarian cancer, improves their progression-free survival, and reduces their risk of relapse or death from this disease. The Primary Investigator of this study is Dr. Antonio González Martín from Clinica Universidad de Navarra (Spain) and president of the Spanish Ovarian Cancer Research Group (GEICO). The New England Journal of Medicine, the world-leading medical journal, published the research in its online last issue.
PARP inhibitor plus chemotherapy improves progression-free survival for advanced ovarian cancer patients
Researchers from The University of Texas MD Anderson Cancer Center reported study results showing that initial treatment with the PARP inhibitor veliparib in combination with chemotherapy significantly increased progression-free survival (PFS) for patients with newly diagnosed, metastatic high-grade serous ovarian cancer, according to the results of the VELIA trial.
Liquid biopsy has prognostic role in colorectal cancer and potential for guiding therapy
Liquid biopsy is likely to play an increasing role in identifying patients with colorectal cancer (CRC) who are likely to relapse after surgery, and has potential for optimising treatment for individual patients, according to new research presented at the ESMO Congress 2019.
His heart stopped. But his golf cart kept going
On a sunny April day in 2018, Bill Doss pushed through his exhaustion and met his buddies for their regular round of golf. As he headed to the final tee, he was rounding a turn in his cart and his world went black.
Cases of legionnaires' disease tied to NC state fair rise to 25
(HealthDay)—The number of cases of Legionnaires' disease tied to the North Carolina Mountain State fair has risen to 25, with one death, according to the state division of public health.
Swiss chocolatier Callebaut all-in on cacao
Swiss chocolatier Barry Callebaut on Friday unveiled a new formulation that packs in the parts of the cacao fruit it used to toss away, taking aim at younger generations.
Going underground in Slovenia ... to prepare for outer space
In Slovenia's dramatically beautiful Karst region, six astronauts have been put through their paces for future missions—not in a flashy futuristic space centre but deep underground in the area's network of cold, dark and muddy caves.
Giant telescope project in Hawaii delayed by protests
Anger is brewing on the Big Island of Hawaii over plans to build a giant telescope on a dormant volcano that is highly sacred to the region's native population.
Keep calm and vape on: UK embraces e-cigarettes, US cautious
While the U.S. scrambles to crack down on vaping, Britain has embraced electronic cigarettes as a powerful tool to help smokers kick the habit.
New blood test capable of detecting multiple types of cancer
A new blood test in development has shown ability to screen for numerous types of cancer with a high degree of accuracy, a trial of the test shows. Dana-Farber Cancer Institute investigators will present the results of the multi-center trial during a session today at the European Society for Medical Oncology (ESMO) 2019 Congress.
Combination immunotherapy drugs herald new hope for melanoma patients with long term survival rates
A combination of two immunotherapy drugs, ipilimumab and nivolumab, has stopped or reversed the progression of advanced melanoma for five years or more in one in two patients, according to a study led by The Royal Marsden NHS Foundation Trust.
One in two patients with metastatic melanoma alive after five years with combination immunotherapy
One in two patients with metastatic melanoma is alive with combination immunotherapy, according to late breaking results of the CheckMate 067 trial presented at the ESMO Congress 2019 in Barcelona, Spain.
Subscribe to:
Posts (Atom)